SAB Biotherapeutics (NASDAQ:SABS – Get Free Report) will be announcing its earnings results on Friday, March 29th.
SAB Biotherapeutics Price Performance
Shares of SABS stock opened at $4.22 on Thursday. The company has a debt-to-equity ratio of 0.23, a quick ratio of 0.34 and a current ratio of 0.34. The company’s 50-day simple moving average is $5.36 and its two-hundred day simple moving average is $2.71. SAB Biotherapeutics has a one year low of $3.66 and a one year high of $14.50.
Hedge Funds Weigh In On SAB Biotherapeutics
Hedge funds have recently added to or reduced their stakes in the stock. Citadel Advisors LLC bought a new position in shares of SAB Biotherapeutics during the third quarter valued at approximately $28,000. State Street Corp boosted its stake in shares of SAB Biotherapeutics by 244.2% during the first quarter. State Street Corp now owns 42,341 shares of the company’s stock valued at $159,000 after purchasing an additional 30,041 shares in the last quarter. Renaissance Technologies LLC bought a new position in shares of SAB Biotherapeutics during the second quarter valued at approximately $45,000. Millennium Management LLC bought a new position in shares of SAB Biotherapeutics during the second quarter valued at approximately $93,000. Finally, HighTower Advisors LLC bought a new position in shares of SAB Biotherapeutics during the fourth quarter valued at approximately $44,000. 7.82% of the stock is currently owned by institutional investors.
Wall Street Analyst Weigh In
Check Out Our Latest Stock Analysis on SAB Biotherapeutics
About SAB Biotherapeutics
SAB Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of immunotherapies based on human antibodies. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases.
See Also
- Five stocks we like better than SAB Biotherapeutics
- Stock Market Upgrades: What Are They?
- Best Bear Market Funds: Top 3 Investment Options to Consider
- What is a buyback in stocks? A comprehensive guide for investors
- Is DraftKings A Good Bet Ahead of Q1 Earnings?
- What Makes a Stock a Good Dividend Stock?
- Mid-Cap Stocks to Outperform the Market This Cycle
Receive News & Ratings for SAB Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SAB Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.